Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

A Clinical Study of T3011 in Subjects With Advanced Melanoma

NCT06214156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

NCT01740401 ·Status: TERMINATED ·Phase: PHASE2

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

NCT04234620 ·Status: UNKNOWN

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

NCT03153085 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma

NCT05827770 ·Status: UNKNOWN ·Phase: PHASE2

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

NCT05723432 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

NCT05087602 ·Status: UNKNOWN ·Phase: PHASE2

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

NCT04462965 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

NCT03422445 ·Status: UNKNOWN ·Phase: PHASE2

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

NCT07099430 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

NCT05907512 ·Status: UNKNOWN ·Phase: PHASE2

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

NCT04274816 ·Status: COMPLETED ·Phase: PHASE1

Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

NCT01449279 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

NCT02738489 ·Status: COMPLETED ·Phase: PHASE1

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

NCT02723006 ·Status: TERMINATED ·Phase: PHASE1

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

NCT05051865 ·Status: UNKNOWN ·Phase: PHASE2

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

NCT04068181 ·Status: COMPLETED ·Phase: PHASE2

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938 ·Status: COMPLETED ·Phase: PHASE2

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

NCT03293784 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04708418 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

NCT05539118 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

NCT03873818 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

NCT01740297 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

NCT05732805 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3